Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis
Eli Lilly's targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) approved by FDA for moderate-to-severe atopic dermatitis in adults and adolescents aged 12+ with at least 40kg body weight, not well controlled by topical therapies. Ebglyss, effective with or without topical corticosteroids, showed 38% of patients achieving clear or almost-clear skin at week 16 in ADvocate trials, compared to 12% with placebo.
Reference News
Eli Lilly's targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) approved by FDA for moderate-to-severe atopic dermatitis in adults and adolescents aged 12+ with at least 40kg body weight, not well controlled by topical therapies. Ebglyss, effective with or without topical corticosteroids, showed 38% of patients achieving clear or almost-clear skin at week 16 in ADvocate trials, compared to 12% with placebo.